Transcenta procures $100 mln

Transcenta, a China and U.S.-based global biotherapeutics company, has secured $100 million in Series B+ funding.

Transcenta, a China and U.S.-based global biotherapeutics company, has secured $100 million in Series B+ funding. CR-CP Life Science Fund and Fortune Capital led the round.

Source: Press Release